Royalty Pharma intends to repurchase $2.0 billion of ... The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. aficamten In December 2024, Cytokinetics announced that ...

Under this structure, which is common among alternative asset managers, Royalty Pharma owns its unique industry-leading ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

Royalty Pharma reports strong Q4 and FY 2024 financial growth, with projected 2025 Portfolio Receipts between $2.9 and $3.05 billion. Royalty Pharma plc reported strong financial results for Q4 ...

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for ...